Harmony Biosciences Holdings HRMY 深 沪
等待开盘 11-26 09:30:00 美东时间
35.34
+0.070
+0.20%
华盛通- 最 高36.1994
- 今 开35.40
- 成交量 91.66万股
- 最 低 34.90
- 昨 收 35.27
- 总市值 20.33亿
- 52周最高 40.93
- 市盈率 静 14.06
- 换手率 1.59%
- 52周最低 25.52
- 委 比 -28.43%
- 总股本 5753.26万
- 历史最高 62.085
- 量 比 0.93
- 振 幅 3.68%
- 历史最低 18.6112
- 每 手 1
- 风险率 3.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $42 Price Target
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $42 price target.
11-24 23:03
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $39
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $36 to $39.
11-07 00:59
Harmony Biosciences Hldgs Affirms FY2025 Sales Guidance of $845.000M-$865.000M vs $845.646M Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2025 sales outlook from $845.000 million-$865.000 million to $845.000 million-$865.000 million vs $845.646 million estimate.
11-04 20:35
Harmony Biosciences Q3 Adj. EPS $1.08 Beats $0.79 Estimate, Sales $239.455M Beat $223.680M Estimate
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.79 by 36.36 percent. This is a 9.09 percent increase over earnings of $0.99 per share from
11-04 20:34
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Earnings Preview For Harmony Biosciences
Harmony Biosciences (NASDAQ:HRMY) is preparing to release its quarterly earning...
11-04 04:01
Harmony Biosciences Reports Record Q3 2025 WAKIX Revenue Of $239M, Raises Full-Year Guidance From $820M-$860M To $845M-$865M
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following:WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025,
10-23 20:17
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
